Skip to main content

Table 1 General characteristics of the study cohort (n = 310) stratified by 90-day survivors and non-survivors

From: Addition of 25-hydroxyvitamin D levels to the Deyo-Charlson Comorbidity Index improves 90-day mortality prediction in critically ill patients

Variable 90-day survivors (n = 251) 90-day non-survivors (n = 59) P value
Age (years) 67 ± 14 69 ± 18 0.43
Sex (%)    0.15
 Female 39 49  
 Male 61 51  
Race (%)    <0.001
 Non-white 5 32  
 White 95 68  
BMI (kg/m2) 28 ± 7 30 ± 8 0.08
Type of patient (%)    <0.001
 Surgical 76 43  
 Medical 24 57  
25OHD (ng/mL) 20 ± 14 12 ± 7 <0.001
APACHE II 14 ± 7 24 ± 9 <0.001
Comorbidities (%)    0.21
 Cardiovascular 92 97  
 Pulmonary 24 46  
 Renal 35 44  
 Hepatic 5 12  
 Sepsis 38 51  
 Trauma 20 36  
DCCI 3 ± 2 5 ± 3 <0.001
  1. Continuous data were reported as means with standard deviations (SDs), medians with interquartile ranges (IQRs), and categorical values were expressed as proportions. Body mass index = BMI, Acute Physiology and Chronic Health Evaluation II = APACHE II; Deyo-Charlson Comorbidity Index = DCCI; intensive care unit = ICU
  2. P-values in italics represent statistically significant results